ITMCTR2000002966尚未招募1 期
Efficacy and safety of topical Xiaozhenzhiyang in the treatment of epidermal growth factor receptor (EGFR) inhibitor-associated rash: a multiple center, randomized, double blinding, placebo-controlled tri
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 85（—）
- 性别
- All
入选标准
- •1. Sign the informed consent, male and female aged at least 18 years old;
- •2. Patients with non-small cell lung cancer (NSCLC) are diagnosed by histology or cytology, EGFR gene mutation-positive;
- •3. The facial rash develops after taking EGFR-TKIs drugs;
- •4. Patient aware of what condition with and understand the content of written informed consent form;
- •5. Life expectancy is greater than or equal to 3 months;
- •6. willing to abide by the agreement, use therapeutic agents according to doctor's advice, and accept regular follow-up with good compliance;
- •7. Complete the questionnaire by yourself or with assistance;
- •8. ECOG PS score 0-3 points;
- •9. All screening laboratory tests are performed according to the program requirements and need to be carried out within 14 days before the first dose; The values of the laboratory tests performed for screening must meet the following criteria:
- •1) Blood routine examination: (no blood transfusion within 14 days before screening, no use of G-CSF, no use of drugs to correct); hemoglobin (HB) >=90 g/L; absolute value of neutrophil count (ANC) >=1.5 x 10^9/L; platelet count (PLT) >=100x10^9/L; white blood cell count (WBC) >=4.0x10^9/L and <=15x10^9/L;
- •2) Biochemical examination: (no blood transfusion or albumin within 14 days before screening): AST and ALT <=1.5 times upper limit of normal (ULN) (if there is tumor liver metastasis, <=5 times ULN); ALP <=2.5 times ULN (if there is tumor bone metastasis, <=5 times ULN); TBiL<=1.5 times ULN; ALB>=30g/L; Cr <=1.5 times ULN, while creatinine clearance (CrCL) >=60 mL/min (Cockcroft-Gault formula); APTT <=1.5 times ULN, while INR or PT <=1.5 times ULN (no anticoagulant therapy).
- •10. Patients who are unwilling to receive randomization can enter the observational cohort for treatment other than the randomized controlled protocol.
排除标准
- •1. Skin rashes caused by other reasons;
- •2. Use of drugs that may affect the results of the trial within 14 days (within the 14 days of day 0 (baseline), concurrent use of topical antibiotics, topical steroids, and other local treatments; use of any systemic antibiotic therapy within seven days before day 0);
- •3. Uncontrolled concurrent diseases, including but not limited to symptomatic congestive heart failure, unstable angina pectoris, arrhythmia or mental illness;
- •4. Subjects with mental illness, alcoholism, drug abuse or substance abuse;
- •5. Based on the investigator's judgment, exclude subjects with any disease that may confuse the results of the study, interfere with the subject's participation in the research process, or are not in the best interest of the subject to participate in the research, or have treatment or laboratory abnormalities Subjects with past and present medical history.
研究者
相似试验
招募中
4 期
Clinical study on the efficacy and safety of Jieyuwan in the treatment of epidemic stress, anxiety and depression (stagnation of liver Qi syndrome)Anxiety and depressionITMCTR2100004368Dongfang Hospital Beijing University of Chinese Medicine
已完成
不适用
Clinical efficacy evaluation of Jingxin Zhidong formula in the treatment of moderate and severe Tic DisorderITMCTR2100004402Guang'anmen Hospital of China Academy of Chinese Medical Sciences
招募中
不适用
Clinical Efficacy Evaluation of Qingzhixiaoyan Decoction in the Treatment of the Hyperlipidemia Caused by Aromatase Inhibitor for the Postmenopausal Breast CancerBreast CancerITMCTR2100004919Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
尚未招募
1 期
Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)ovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003243Beijing University of Chinese Medicine Third Affiliated Hospital
已完成
不适用
Efficacy and safety of Yijin-tang on polycystic ovarian syndrome: A single-arm pilot studyEndocrine, nutritional and metabolic diseaseKCT0002749Kyung Hee University Oriental Medicine Hospital at Gangdong15